Flumazenil: a benzodiazepine antagonist.

Clinical pharmacy Pub Date : 1993-09-01
E J Hoffman, E W Warren
{"title":"Flumazenil: a benzodiazepine antagonist.","authors":"E J Hoffman,&nbsp;E W Warren","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The mechanism of action, pharmacokinetics, and use of flumazenil in benzodiazepine overdose, as well as in the management of other disease states, are reviewed. Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists. Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy. It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy. It appears to be effective in reversing sedation induced by midazolam or diazepam, and case reports suggest that it is useful in awakening comatose patients, although its clinical utility is questionable. Flumazenil has proved useful in reversing conscious sedation in critically ill patients, although response may be dose dependent. Animal models indicate that flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Adverse reactions include CNS manifestations, resedation, cardiovascular effects, seizures, and alterations in intracranial pressure and cerebral perfusion pressure. Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected. It may be beneficial after surgery when benzodiazepines have been used as part of anesthesia and after a diagnostic or surgical procedure when assessment of CNS function is necessary.</p>","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"12 9","pages":"641-56; quiz 699-701"},"PeriodicalIF":0.0000,"publicationDate":"1993-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The mechanism of action, pharmacokinetics, and use of flumazenil in benzodiazepine overdose, as well as in the management of other disease states, are reviewed. Flumazenil interacts at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists and inverse agonists. Flumazenil has been studied for a variety of indications, including as an antidote to benzodiazepine overdose and for awakening of comatose patients, reversal of sedation after surgery and in critically ill patients, and management of hepatic encephalopathy. It improves the level of consciousness in patients with benzodiazepine overdose; however, resedation may occur within one to two hours after administration, so repeated doses or a continuous infusion may be required to maintain therapeutic efficacy. It appears to be effective in reversing sedation induced by midazolam or diazepam, and case reports suggest that it is useful in awakening comatose patients, although its clinical utility is questionable. Flumazenil has proved useful in reversing conscious sedation in critically ill patients, although response may be dose dependent. Animal models indicate that flumazenil is of some benefit in hepatic encephalopathy, but until well-designed clinical trials are conducted, hepatic encephalopathy must be considered an investigational indication for flumazenil. Adverse reactions include CNS manifestations, resedation, cardiovascular effects, seizures, and alterations in intracranial pressure and cerebral perfusion pressure. Hepatic dysfunction results in a substantial change in the pharmacokinetic profile of flumazenil; therefore, dosage adjustment may be necessary in patients with hepatic dysfunction or in those receiving medications that alter flumazenil metabolism. Flumazenil has been shown to reverse sedation caused by intoxication with benzodiazepines alone or benzodiazepines in combination with other agents, but it should not be used when cyclic antidepressant intoxication is suspected. It may be beneficial after surgery when benzodiazepines have been used as part of anesthesia and after a diagnostic or surgical procedure when assessment of CNS function is necessary.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氟马西尼:苯二氮卓类拮抗剂。
本文综述了氟马西尼在苯二氮卓类药物过量以及其他疾病状态管理中的作用机制、药代动力学和使用。氟马西尼与中枢苯二氮卓受体相互作用,拮抗或逆转苯二氮卓激动剂和逆激动剂的行为、神经和电生理效应。对氟马西尼的各种适应症进行了研究,包括作为苯二氮卓类药物过量的解毒剂和昏迷患者的唤醒,手术后和危重患者镇静的逆转,以及肝性脑病的治疗。提高苯二氮卓类药物过量患者的意识水平;然而,镇静可能在给药后1至2小时内发生,因此可能需要重复给药或连续输注以保持治疗效果。它似乎可以有效逆转咪达唑仑或地西泮引起的镇静,病例报告表明它对唤醒昏迷患者有用,尽管其临床效用值得怀疑。氟马西尼已被证明可用于逆转危重病人的清醒镇静,尽管反应可能是剂量依赖性的。动物模型表明氟马西尼对肝性脑病有一定的益处,但在进行精心设计的临床试验之前,必须将肝性脑病视为氟马西尼的研究指征。不良反应包括中枢神经系统表现、镇静、心血管作用、癫痫发作以及颅内压和脑灌注压的改变。肝功能障碍导致氟马西尼的药代动力学特征发生实质性变化;因此,对于肝功能障碍患者或接受改变氟马西尼代谢药物的患者,可能需要调整剂量。氟马西尼已被证明可以逆转苯二氮卓类药物单独或苯二氮卓类药物与其他药物联合中毒引起的镇静,但当怀疑是循环抗抑郁药物中毒时,不应使用氟马西尼。在手术后,当苯二氮卓类药物作为麻醉的一部分使用时,在诊断或外科手术后,当需要评估中枢神经系统功能时,它可能是有益的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The assortment analysis of chlorhexidine-containing medicines and procurement data of state and municipal organizations Laboratory toxicological diagnosis of trazodone intoxications The analysis of approaches to conducting bioequivalence studies and the policy of “transparency” of their results in Ukraine, the United States and the European Union Subunit compositions of GABAA receptors determining the diversity of physiological processes and neurotropic properties of medicines Ways of medicinal prevention and treatment of doxorubicin-induced cardiomyopathy in oncological patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1